Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    • Home
    • observations

    Tag: observations

    You Searched For "observations"
    Lupin gets 2 observations from USFDA for Nagpur facility

    Lupin gets 2 observations from USFDA for Nagpur facility

    Medical Dialogues Bureau13 Jan 2020 11:58 AM IST
    Drug firm Lupin on Saturday said it has received two observations from the US health regulator following the inspection of its Nagpur manufacturing...
    Dr Reddy

    Dr Reddy's gets EIR for Vizag plant, but inspection not closed

    Ruby Khatun Khatun22 Nov 2017 11:06 AM IST
    New Delhi: Dr. Reddy's Laboratories said it has received an establishment inspection report (EIR) from the US health regulator for its formulation...
    Mylan seeks EMA approval for 2 biosimilars

    Mylan seeks EMA approval for 2 biosimilars

    Ruby Khatun Khatun9 Nov 2017 10:32 AM IST
    New Delhi: Biocon said that its partner Mylan has re-submitted marketing authorization applications with the European Medicines Agency for two...
    Divis Labs gets 6 USFDA observations for Vizag unit

    Divis Labs gets 6 USFDA observations for Vizag unit

    Ruby Khatun Khatun21 Sept 2017 10:27 AM IST
    New Delhi: Drug firm Divis Laboratories on Thursday said it has received six new observations from the US Food and Drug Administration (USFDA) after...
    Dr Reddys Vizag unit gets 6 observations by German regulator

    Dr Reddys Vizag unit gets 6 observations by German regulator

    Ruby Khatun Khatun9 Sept 2017 9:32 AM IST
    New Delhi: Dr Reddy's Laboratories (DRL) said the German drug regulator has concluded the audit of its Visakhapatnam formulations facility with six...

    Popular Stories

    • Email: info@medicaldialogues.in
    • Phone: 011 - 4372 0751

    Website Last Updated On : 13 Oct 2022 5:14 AM GMT
    Company
    • About Us
    • Contact Us
    • Our Team
    • Reach our Editor
    • Feedback
    • Submit Article
    Ads & Legal
    • Advertise
    • Advertise Policy
    • Terms and Conditions
    • Privacy Policy
    • Editorial Policy
    • Comments Policy
    • Disclamier
    Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

    Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

    © 2025 - Medical Dialogues. All Rights Reserved.
    Powered By: Hocalwire
    X
    We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok